Inhibition of prostaglandin effects by ouabain in the canine vascular tissue.
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D004285:Dogs; D008638:Mesenteric Arteries / Q000187:drug effects* / Q000201:enzymology; D008642:Mesenteric Veins / Q000187:drug effects* / Q000201:enzymology; D009119:Muscle Contraction / Q000187:drug effects*; D009638:Norepinephrine / Q000494:pharmacology; D010042:Ouabain / Q000494:pharmacology*; D010208:Papaverine / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology; D011453:Prostaglandins / Q000494:pharmacology*; D012964:Sodium / Q000378:metabolism; D013779:Tetrodotoxin / Q000494:pharmacology
D011453:Prostaglandins; D010643:Phenoxybenzamine; D013779:Tetrodotoxin; D010042:Ouabain; D001285:Atropine; D012964:Sodium; D011433:Propranolol; D010208:Papaverine; D000251:Adenosine Triphosphatases; D011188:Potassium; D009638:Norepinephrine